After chronic myelogenous leukemia: tyrosine kinase inhibitors in other hematologic malignancies.

@article{Wadleigh2005AfterCM,
  title={After chronic myelogenous leukemia: tyrosine kinase inhibitors in other hematologic malignancies.},
  author={Martha Wadleigh and Daniel J. Deangelo and James D Griffin and Richard M Stone},
  journal={Blood},
  year={2005},
  volume={105 1},
  pages={22-30}
}
Tyrosine kinases phosphorylate proteins on tyrosine residues, producing a biologic signal that influences many aspects of cellular function including cell growth, proliferation, differentiation, and death. Constitutive or unregulated activity through mutation or overexpression of these enzymes is a common pathologic feature in many acute and chronic leukemias. Inhibition of tyrosine kinases represents a strategy to disrupt signaling pathways that promote neoplastic growth and survival in… CONTINUE READING
27 Citations
156 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 27 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 156 references

Imatinib mesylate (Gleevec) for disease relapse following allogeneic bone marrow transplantation

  • RJ Soiffer, I Galinsky, D. DeAngelo
  • [abstract]. Blood. 2001;98:400a
  • 2005

Similar Papers

Loading similar papers…